scholarly journals Is Cystatin C a promising marker of renal function, at birth, in neonates prenatally diagnosed with congenital kidney anomalies?

2012 ◽  
Vol 27 (9) ◽  
pp. 3477-3482 ◽  
Author(s):  
P. Parvex ◽  
C. Combescure ◽  
M. Rodriguez ◽  
E. Girardin
2015 ◽  
Vol 3 (1) ◽  
pp. 40-49 ◽  
Author(s):  
W.H. Wilson Tang ◽  
Matthias Dupont ◽  
Adrian F. Hernandez ◽  
Adriaan A. Voors ◽  
Amy P. Hsu ◽  
...  

2009 ◽  
Vol 112 (3) ◽  
pp. c164-c170 ◽  
Author(s):  
Néstor Fontseré ◽  
Vicens Esteve ◽  
Ana Saurina ◽  
Mónica Pou ◽  
Nuria Barba ◽  
...  

2016 ◽  
Vol 11 ◽  
pp. BMI.S39199 ◽  
Author(s):  
Habib Mawad ◽  
Louis-Philippe Laurin ◽  
Jean-François Naud ◽  
François A. Leblond ◽  
Nathalie Henley ◽  
...  

Objective The aim of our study is to describe the changes in urinary and serum levels of novel biomarkers after gadolinium contrast administration in patients with normal renal function. Methods We measured four biomarkers in 28 volunteers: interleukin-18 (IL-18), N-acetyl-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin, and cystatin C. Urinary and serum samples were collected at 0, 3, and 24 hours following gadolinium administration. Results Baseline serum creatinine was 57.8 ± 34.5 μmol/L and remained stable. Urinary IL-18 levels increased significantly at three hours (10.7 vs. 7.3 ng/mg creatinine; P < 0.05). Similarly, urinary NAG levels increased significantly at three hours (3.9 vs. 2.2 IU/mg creatinine; P < 0.001). For both these markers, the difference was no longer significant at 24 hours. No statistically significant differences were observed for urinary and serum neutrophil gelatinase-associated lipocalin levels and for serum cystatin C levels. Conclusions Urinary IL-18 and NAG levels increased transiently after administration of gadolinium-based contrast agents in patients with normal renal function.


Obesity ◽  
2012 ◽  
Vol 20 (6) ◽  
pp. 1136-1136 ◽  
Author(s):  
João V. Salgado ◽  
Bernardete J. Salgado ◽  
Francisco A. Neves
Keyword(s):  

2020 ◽  
Vol 155 (9) ◽  
pp. 419-420
Author(s):  
Ana Cristina Andrade López ◽  
José Joaquín Bande Fernández ◽  
Carmen Díaz Corte

2008 ◽  
Vol 56 (8) ◽  
pp. 1434-1441 ◽  
Author(s):  
Andrea Z. LaCroix ◽  
Jennifer S. Lee ◽  
LieLing Wu ◽  
Jane A. Cauley ◽  
Michael G. Shlipak ◽  
...  

2009 ◽  
Vol 54 (2) ◽  
pp. 778-782 ◽  
Author(s):  
Akihiro Tanaka ◽  
Tetsuya Aiba ◽  
Takashi Otsuka ◽  
Katsuya Suemaru ◽  
Tatsuya Nishimiya ◽  
...  

ABSTRACT We determined the population pharmacokinetics of vancomycin (VAN) using the glomerular filtration rate (GFR) estimated from the serum cystatin C concentration. We examined the predictive performance of the trough serum VAN concentration for determination of the initial dose by using a new model for the analysis of the population pharmacokinetic parameters. Data for 86 patients were used to estimate the values of the population pharmacokinetic parameters. Analysis with a nonlinear mixed-effects modeling program was done by using a one-compartment model. Data for 78 patients were used to evaluate the predictive performance of the new model for the analysis of population pharmacokinetic parameters. The estimated GFR values determined by using Hoek's formula correlated linearly with VAN clearance (VAN clearance [ml/min] = 0.825 × GFR). The mean volume of distribution was 0.864 (liters/kg). The interindividual variability of VAN clearance was 19.8%. The accuracy of the prediction determined by use of the new model was statistically better than that determined by use of the Japanese nomogram-based model because the 95% confidence interval (−3.45 to −1.38) of the difference in each value of the mean absolute error (−2.41) did not include 0. Use of the serum cystatin C concentration as a marker of renal function for prediction of serum VAN concentrations may be useful.


Sign in / Sign up

Export Citation Format

Share Document